INNV Quote, Financials, Valuation and Earnings

American Shared Hospital Services has a net margin of -6.33% compared to InnovAge Holding's net margin of -2.96%. InnovAge Holding's return on equity of -8.76% beat American Shared Hospital Services's return on equity of 13.75%.

InnovAge Holding has a consensus price target of $5.00, signalling upside risk potential of 40.06%. On the other hand American Shared Hospital Services has an analysts' consensus of $4.84 which suggests that it could grow by 70.72%. Given that American Shared Hospital Services has higher upside potential than InnovAge Holding, analysts believe American Shared Hospital Services is more attractive than InnovAge Holding.

InnovAge Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.356, suggesting its less volatile than the S&P 500 by 64.359%.

InnovAge Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InnovAge Holding pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.

InnovAge Holding quarterly revenues are $209M, which are larger than American Shared Hospital Services quarterly revenues of $7M. InnovAge Holding's net income of -$13.2M is lower than American Shared Hospital Services's net income of -$207K. Notably, InnovAge Holding's price-to-earnings ratio is -- while American Shared Hospital Services's PE ratio is 8.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InnovAge Holding is 0.60x versus 0.67x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -6.33% compared to InnovAge Holding's net margin of 3.55%. InnovAge Holding's return on equity of -8.76% beat Cryo-Cell International's return on equity of --.

InnovAge Holding has a consensus price target of $5.00, signalling upside risk potential of 40.06%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 66.83%. Given that Cryo-Cell International has higher upside potential than InnovAge Holding, analysts believe Cryo-Cell International is more attractive than InnovAge Holding.

InnovAge Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.595%.

InnovAge Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 9.81% to investors and pays a quarterly dividend of $0.25 per share. InnovAge Holding pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

InnovAge Holding quarterly revenues are $209M, which are larger than Cryo-Cell International quarterly revenues of $8M. InnovAge Holding's net income of -$13.2M is lower than Cryo-Cell International's net income of $282.9K. Notably, InnovAge Holding's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 509.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InnovAge Holding is 0.60x versus 1.30x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

National Healthcare has a net margin of -6.33% compared to InnovAge Holding's net margin of 1.65%. InnovAge Holding's return on equity of -8.76% beat National Healthcare's return on equity of 10.72%.

InnovAge Holding has a consensus price target of $5.00, signalling upside risk potential of 40.06%. On the other hand National Healthcare has an analysts' consensus of -- which suggests that it could fall by --. Given that InnovAge Holding has higher upside potential than National Healthcare, analysts believe InnovAge Holding is more attractive than National Healthcare.

InnovAge Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Healthcare has a beta of 0.512, suggesting its less volatile than the S&P 500 by 48.765%.

InnovAge Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Healthcare offers a yield of 2.58% to investors and pays a quarterly dividend of $0.61 per share. InnovAge Holding pays -- of its earnings as a dividend. National Healthcare pays out 36.27% of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

InnovAge Holding quarterly revenues are $209M, which are smaller than National Healthcare quarterly revenues of $369.4M. InnovAge Holding's net income of -$13.2M is lower than National Healthcare's net income of $6.1M. Notably, InnovAge Holding's price-to-earnings ratio is -- while National Healthcare's PE ratio is 14.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InnovAge Holding is 0.60x versus 1.14x for National Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Sonida Senior Living has a net margin of -6.33% compared to InnovAge Holding's net margin of -5.99%. InnovAge Holding's return on equity of -8.76% beat Sonida Senior Living's return on equity of -4.58%.

InnovAge Holding has a consensus price target of $5.00, signalling upside risk potential of 40.06%. On the other hand Sonida Senior Living has an analysts' consensus of $25.00 which suggests that it could grow by 1.67%. Given that InnovAge Holding has higher upside potential than Sonida Senior Living, analysts believe InnovAge Holding is more attractive than Sonida Senior Living.

InnovAge Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sonida Senior Living has a beta of 1.143, suggesting its more volatile than the S&P 500 by 14.264%.

InnovAge Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sonida Senior Living offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InnovAge Holding pays -- of its earnings as a dividend. Sonida Senior Living pays out -136.86% of its earnings as a dividend.

InnovAge Holding quarterly revenues are $209M, which are larger than Sonida Senior Living quarterly revenues of $91.9M. InnovAge Holding's net income of -$13.2M is lower than Sonida Senior Living's net income of -$5.5M. Notably, InnovAge Holding's price-to-earnings ratio is -- while Sonida Senior Living's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InnovAge Holding is 0.60x versus 1.15x for Sonida Senior Living. Usually stocks with elevated PS ratios are considered overvalued.